Summary The in vitro and in vivo stability and anti-tumour efficacy of the anti-EGFR/anti-CD3 bispecific monoclonal antibody (biMAb), M26.1, were analysed. The interaction of the intact biMAb with Fc receptor I (Fc'yRI) present on human leucocytes was not observed when the antibody was used as an F(ab')2 fragment. A CD8+ T-cell clone coated with M26
The epidermal growth factor receptor (EGFR), a 170 kDa transmembrane glycoprotein with tyrosine kinase activity, is overexpressed in a wide range of human malignancies (Gullick, 1991) . Increased EGFR expression correlates with a poor clinical outcome in patients with cancer of the lung, bladder, oesophagus, breast, cervix and ovary (Hendler et al., 1989; Fox et al., 1994) . Only in glial and head and neck tumours has EGFR over-expression been frequently associated with amplification of the gene (Libermann et al., 1985; Chaffanet et al., 1992; Wong et al., 1992) , and on tumour cells expression levels can be increased by several orders of magnitude, suggesting the feasibility of therapeutic strategies that exploit the differential levels of EGFR expression on tumours vs normal cells. Like other growth factor receptors on tumour cells, EGFR may represent a suitable target molecule for antibody-driven therapy. A panel of anti-EGFR monoclonal antibodies (MAbs) is now available (Gill et al., 1984; Rodeck et al., 1987; Mendelsohn 1990 ) and several of them have been applied in preclinical (Bender et al., 1992; Baselga et al., 1993; Fan et al., 1993a,b) and clinical immunotherapeutic settings (Kalofonos et al., 1989; Divgi et al., 1991; Brady et al., 1992) .
MAbs specific for tumour-associated antigens (TAAs) have been used to construct bispecific reagents in conjunction with MAbs against T-lymphocyte surface molecules capable of cell activation, such as the CD3/TCR complex (Segal et al., 1988; Beun et al., 1994) . These biMAbs can target T-cell-mediated cytotoxicity and induce lysis of target cells in an MHCindependent manner. BiMAbs have been employed to arm large numbers of effector cells in vitro (Pupa et al., 1988) , which have been used to control tumour cell growth in nude mice bearing human cancer xenografts (Mezzanzanica et al., 1991a; Renner et al., 1994) and also in humans with ovarian (Bolhuis et al., 1992 ) and brain tumours (Nitta et al., 1990 (Ferrini et al., 1993) .
In the present preclinical analysis we show that the M26.1 biMAb F(ab')2 retains its ability to trigger T-cell (Mariani et al., 1991) .
Pharmacokinetics studies Pathogen-free female athymic mice (nu/nu CD1 background) or normal BALB/C mice, 6-8 weeks old, were obtained from Charles River (Calco, Como, Italy) . Mice were held for 1-2 weeks before initiating experiments. Animals were housed under sterile conditions and received autoclaved food and water. According to their sensitivity to labelling procedures, M26.1 and its F(ab')2 were labelled with 1251I using lodogen, whereas anti-EGFR and its F(ab')2 were labelled using the Anti-EGFR/Anti-CD3 F(ab')2 biMAb stability and efficacy DRM Negri et al 929 lactoperoxidase method (Marchalonis, 1969) . Mice were injected i.p. with 1.8-3.4 ig of 251I-labelled intact MAb or F(ab')2 (sp. act. 2.7-5.2 ILCi sg-') or with 10 lAg of unlabelled F(ab')2 M26.1. Blood samples were collected at various times (from 30min to 72h) after administration (three mice for each time point) and serum was recovered. For mice injected with radiolabelled reagents, an aliquot of each serum sample was counted in a gamma-counter and protein-bound radioactivity was measured by paper chromatography in 10% trichloroacetic acid. For mice injected with unlabelled reagent, the presence of active F(ab')2 in blood serum samples were evaluated in a standard 4 h 51Cr-release assay. Pharmacokinetic parameters were calculated using the MKMODEL modelling program (Biosoft, Cambridge, UK).
Activation and coating of human PBL Freshly obtained PBLs from healthy donors were activated, expanded and coated with M26. 1 biMAb F(ab')2 as described (Bolhuis et al., 1992) .
Cytotoxicity assays Activated lymphocytes, T-cell polyclonal lines and T-cell clones (Ferrini et al., 1989) were used as effector cells and IGROVI cells were used as target at effector-target cell ratios from 10:1 to 40:1 in a 4h 51Cr-release assay. For analysis of MAb-induced cytotoxicity, various concentrations of biMAb or F(ab')2 were added at the start of the assay. To test whether biMAbs maintained their ability to trigger cytolysis, coated lymphocytes were incubated in vitro for different times in the presence of OCAF or GCF (final dilution, 1:2). Unwashed lymphocytes were added at a given time to labelled target cells at an effector-to-target cell ratio of 40:1 and specific lysis was assayed in a 4 h 5'Cr-release assay. Per cent lysis and biMAb or F(ab')2 concentrations producing half-maximal cytolysis (ED50) were evaluated as described.
Stability of F(ab')2 biMAb
An aliquot of 5 IlI of 1251I-labelled F(ab')2 biMAb was incubated at 37°C with 45 pl of BALB/C mouse or human sera, OCAF and GCF samples, or saline. At various times from 30 min to 72 h, 1 IlI (2000 c.p.m.) of each sample was analysed by 4-15% SDS-PAGE, autoradiography for a week at -80°C and densitometry.
In vivo activity of F(ab')2 biMAb Five groups of athymic mice (8-12 animals per group, see Table III ) were injected i.p. with 107 IGROVI cells, maintained in vivo by serial transplants, on day 0. Animals were injected i.p., twice a day, on days + 3 and + 4 with various combinations of activated PBLs and parental MAbs or biMAb. Mice were monitored for abdominal swelling and mortality. Treatment effects were compared by Wilcoxon and log-rank non-parametric tests.
Results

BiMAb FcR interaction
We previously described a heteroisotypic (IgGl/IgG2a) anti-EGFR/anti-CD3 biMAb M26. 1, secreted by a hybrid hybridoma (Ferrini et al., 1993 others (Sharkey et al., 1991) . The shorter t1/2P of M26.1 F(ab')2 as compared to parental anti-EGFR F(ab')2 might reflect a more rapid degradation of the heteroisotypic form. When biMAb and parental anti-EGFR MAb were compared, similar values were obtained.
In vivo anti-tumour activity of human T cells targeted by biMAb F(ab')2
The in vivo anti-tumour activity of PBLs targeted by biMAb F(ab')2 was evaluated in a preclinical model of human tumour xenografts in nude mice. Intraperitoneal injection of 107 IGROVI cells into the mice caused death rapidly, with a mean survival time of 10.75 days (Table III) Anti-EGFR/Anti-CD3 F(ab)2 biMAb stability and efficacy DRM Negri et al 931 the diaphragm and liver. Nude mice bearing 3 day i.p. IGROVI tumours and treated i.p. on day 3 and 4 with PBLs alone, PBLs plus parental MAbs or M26. 1 F(ab')2 alone showed no increase in mean survival time (10.91 * . 11.83 days) as compared to untreated mice (10.75 ± 0.41 days), whereas mice treated with activated PBLs coated with M26.1 F(ab')2 showed a significant increase in mean survival time (23.17 ± 2.67 days, P = 0.003) (Table III, Figure 4 ).
Discussion
In this report, we show that the anti-EGFR/anti-CD3 biMAb M26. 1, following removal of the Fc region, retains its ability to target human T lymphocytes against EGFR+ tumours in vitro in the presence of different mouse and human biological fluids, and in vivo in a xenotransplanted mouse model. Mice were injected i.p. with tumour cells on day 0 and were treated on days +3 and +4 twice a day with: physiological solution; (0), PBLs alone (A), biMAb F(ab')2 alone (+), PBL-+ parental F(ab')2 (0) or PBLs coated with biMAb F(ab')2 (X).
(For doses see Table III ). (Segal et al., 1988; Fanger et al., 1992 In view of its heteroisotypic nature (IgGl/IgG2a), we investigated the in vitro and in vivo stability of M26.1 F(ab')2 fragments. As previously reported, the pepsin cleavage site for IgGl and IgG2a is localised in different regions, i.e. the reaction produces a smaller segment in IgGl than in IgG2a (Parham, 1983) . Consequently, F(ab')2 of the heteroisotypic biMAb is formed by two fragments of different length which might lead to an increased susceptibility to proteolytic or reducing activities. Indeed, our analysis of the stability of the biMAb F(ab')2 vs the parental anti-EGFR fragment in the presence of mouse and human sera or pathological human fluids revealed a variable level of reduction of intact F(ab')2 to monovalent F(ab') after incubation with pathological fluids, particularly in the case of GCFs. As expected, the phenomenon was more evident with biMAb F(ab')2. However F(ab')2 biMAb-coated lymphocytes maintained the ability to lyse EGFR+ targets even after 24 h and 48 h of incubation with GCFs and OCAFs respectively. Thus, it appears that biMAb F(ab')2, when present as a soluble molecule in some biological fluids, but not when bound to T cells, can lose functional activity as a consequence of partial reduction.
GCF and ascitic fluids have been shown to contain immunosuppressive factors, such as TGF-P (Hirte and Clark, 1991) , which can inhibit in vitro activation and proliferation of lytic effector cells (Wahl et al., 1989) (Fan et al., 1993b; Van Dijk et al., 1991) . To verify the in vivo anti-tumour activity of our reagent, we chose a preclinical survival model of nude mice using the EGFR+ human ovarian carcinoma cell line IGROVI. This model was selected because the tumour remains localised to the peritoneum and can therefore be treated with local immunotherapy. Specific in vivo targeting therapy using in vitro-activated lymphocytes coupled with biMAb has been described (Nitta et al., 1990; Bolhuis et al., 1992) , and other clinical trials with different biMAbs are currently underway. Consistent with data from preclinical and clinical studies, we find that mice treated with activated human PBLs coated with M26.1 F(ab')2 survive significantly longer, although the treatment did not completely eradicate the implanted tumour. This failure probably reflects the high growth rate of the xenograft model which causes death more rapidly (mean survival time = 10.75 days) than in other preclinical models (Mezzanzanica et al., 1991a; Renner et al., 1994) . More aggressive treatment might further improve survival rates and eventually lead to tumour cure.
This biMAb retargeting approach offers several advantages over others that utilise anti-EGFR MAbs therapeutically. Targeting of T cells by biMAb should allow a local release of inhibitory cytokines at the tumour site (Qian et al., 1991) which might act on all cells within a tumour, including cells that were sterically inaccessible to targeted PBLs or that had lost antigen expression. In our experimental model, adverse effects on normal tissues would not be expected in mice because the biMAb does not bind to the mouse EGFR (Valota et al., submitted) and to murine CD3 (Ferrini et al., 1993) . Since human epithelia express moderate/low EGFR levels (Rodriguez et al., 1991; Banks-Schlegel et al., 1986 ) the systemic use of anti-EGFR MAbs in humans must be considered with caution. However, bispecific M26. 1 F(ab')2 might be used as a targeting agent for local treatment of tumours such as gliomas or ovarian cancers that express variable levels of EGFR molecules, but whose surrounding accessible normal tissues are EGFR negative.
